ALLK Allakos
- 0.660
- +0.010+1.54%
- 0.630
- -0.030-4.50%
Allakos News
Jasper Gains 11% on Data for Briquilimab in Urticaria
Analysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)
12 Health Care Stocks Moving In Friday's After-Market Session
TD Cowen Maintains Allakos(ALLK.US) With Hold Rating
Conduit Pharmaceuticals CDT AZN Stake; Allakos ALLK Phase 1 Data
Allakos Perks up After Early-stage Data for Lead Asset
LifeSci Capital Maintains Allakos(ALLK.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
Allakos Subcutaneous Therapy for Mast Cells-Related Diseases 'Well-Tolerated;' Shares Up After Hours
Allakos Progress Update on AK006 and Future Milestones
Allakos Announces Phase 1 Trial Results Of Subcutaneous AK006 In Healthy Volunteers; Subcutaneously Administered AK006 Showed ~77% Bioavailability And Prolonged Receptor Occupancy On Mast Cells; Was Well-tolerated With A Favorable Safety Profile
Express News | Allakos Inc: Top-Line Phase 1 Results of Intravenous Ak006 in Patients With Csu Are Expected in Early Q1 of 2025
Express News | Allakos- Ak006 Well-Tolerated With Favorable Safety Profile
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
Express News | Allakos Announces Phase 1 Trial Results of Subcutaneous Ak006 in Healthy Volunteers
12 Health Care Stocks Moving In Friday's Pre-Market Session
JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3
Allakos Gets Nasdaq Noncompliance Notice on Minimum Bid Price
Maintaining Hold on Allakos: Weighing AK006 Promise Against Clinical Setbacks
Express News | Allakos Inc : Jefferies Cuts Target Price to $0.85 From $1
Analysis
Price Target
No Data
No Data